Dr. Vega is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
BIDMC/HMS - Neurosurgery
110 Francis St., Lowry Ste 3B
Boston, MA 02215Phone+1 617-632-7246Fax+1 617-632-0949
Summary
- Dr. Rafael Vega is a board-certified neurosurgeon in Boston, MA and affiliated with Beth Israel Deaconess Medical Center, Harvard Medical School. He received his fellowship training at MD Anderson in Neurosurgical Oncology. He serves as Director of the Brain Tumor Center at BIDMC and is a Member of Dana-Farber/Harvard Cancer Center. He specializes in the treatment of malignant/benign brain tumors.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Neurosurgical Oncology, 2018 - 2019
- Virginia Commonwealth University Health SystemResidency, Neurological Surgery, 2011 - 2018
- University of Virginia Medical CenterPost-Doctoral Fellowship, Neuro-Oncology, 2015 - 2016
- University of Illinois College of MedicineClass of 2011, MD
- Northwestern UniversityPhD, Chemistry of Life Processes, 2003 - 2007
- University of ColoradoBS, Chemistry, with High Distinction, 2000 - 2003
Certifications & Licensure
- MA State Medical License 2019 - 2025
- NH State Medical License 2024 - 2024
- American Board of Neurological Surgery Neurological Surgery
- The Society of Neurological SurgeonsCommittee on Advanced Subspecialty Training (CAST) in Neurosurgical Oncology
Awards, Honors, & Recognition
- Boston Magazine Top Doctor 2024
- Fellow of the Congress of Neurological Surgeons (FCNS) Congress of Neurological Surgeons, 2024
- Fellow of the American College of Surgeons (FACS) American College of Surgeons, 2024
- Join now to see all
Clinical Trials
- Surgical Pembro +/- Olaparib w TMZ for rGBM Start of enrollment: 2022 Oct 21
Roles: Contact
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Start of enrollment: 2022 Jun 20
Publications & Presentations
PubMed
- 35 citationsMinimizing transfusion requirements for children undergoing craniosynostosis repair: the CHoR protocolRafael A. Vega, Camila Lyon, Jeannette F Kierce, Gary W. Tye, Ann M. Ritter
Journal of Neurosurgery. Pediatrics. 2014-08-01 - 29 citationsNatural History of Acute Subdural Hematoma.Rafael A. Vega, Alex B. Valadka
Neurosurgery Clinics of North America. 2017-04-01 - 5 citationsSpatial regulation of gene expression in nonsyndromic sagittal craniosynostosisGarrett N Cyprus, Jefferson W. Overlin, Rafael A. Vega, Ann M. Ritter, Rene Olivares-Navarrete
Journal of Neurosurgery. Pediatrics. 2018-09-14
Books/Book Chapters
Committees
- Co-Chair, CNS Journal Club Podcast 2019 - Present
Research History
- Principle Investigator, Surgical Neuro-Oncology Outcomes LaboratoryBeth Israel Deaconess Medical Center / Harvard Medical School2020 - Present
Professional Memberships
- Member
- Member
- Member
- Society of Neuro-OncologyMember
- North American Skull Base SocietyMember
Other Languages
- Spanish
External Links
- DF/HCC Profilehttps://www.dfhcc.harvard.edu/insider/member-detail/member/rafael-a-vega-md-phd/
- BIDMC Brain Tumor Centerhttps://www.bidmc.org/centers-and-departments/cancer-center/cancer-center-programs-and-services/brain-tumor-program
- BIDMC Neurosurgeryhttps://www.bidmc.org/centers-and-departments/neurosurgery
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: